The biotech investment climate sank into deep insecurity by the close of 2015, as shown in EP Vantage‘s new “Pharma & Biotech 2015 in Review” report. The flutterings around companies raising capital, via venture capital or IPO, diminished – which invites a retrospective on the investment environment in years past. Perhaps this will help inform how cash-hungry companies will fare this year.
{iframe}http://medcitynews.com/2016/03/369724/{/iframe}